Linked Life Data

11892917

Source:http://linkedlifedata.com/resource/pubmed/id/11892917

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2002-3-14
pubmed:abstractText
During the 15 years since the cloning of the erythropoietin (EPO) gene, the recombinant hormone has become an extraordinarily successful therapeutic for the treatment of renal and several nonrenal anemias. Considerable insight was gained into the adverse consequences of chronic reduction in hemoglobin levels on quality of life, physiological functions and survival. Precise cost-benefit relationships, however, are still lacking and target hemoglobin levels remain controversial. Nevertheless, given the wide application and potential of erythropoietic stimulation, there is growing interest in alternative but related strategies, including the development of second generation molecule EPO-mimetics, modulators of receptor activity and EPO gene therapy.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1472-4472
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1081-5
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
The potential of erythropoietin and related strategies to stimulate erythropoiesis.
pubmed:affiliation
Department of Nephrology and Medical Intensive Care, Charité, Campus Virchow Klinikum, Berlin, Germany. kai-uwe.eckardt@charite.de
pubmed:publicationType
Journal Article, Review